

## Plasmodium yoelii subsp. yoelii, Strain YM

### Catalog No. MRA-755

### For research use only. Not for human use.

#### Contributor:

David Walliker, Ph.D., Professor, Institute of Cell, Animal and Population Biology, Division of Biological Sciences, Ashworth Laboratories, University of Edinburgh, Edinburgh, Scotland

#### Manufacturer:

BEI Resources

#### Product Description:

Protozoa Classification: *Plasmodiidae*, *Plasmodium*

Species: *Plasmodium yoelii* subsp. *yoelii*

Strain: YM

Original Source: *Plasmodium yoelii* subsp. *yoelii* (*P. yoelii* subsp. *yoelii*), strain YM is a highly virulent clone derived from isolate 17X. *P. yoelii* subsp. *yoelii*, strain 17X was isolated by I. Landau from wild-caught thicket rat (*Thamnomys rutilans*) no. 17X, at La Maboké Field Station in Central African Republic, April 1965.<sup>1,2</sup>

Comments: The original 17X isolate was sent to Paris, France, then New York University (NYU). A highly virulent line, which emerged at NYU, was sent to Edinburgh by M. Yoeli, where it was denoted YM and cloned in December 1973 by dilution into mice.<sup>2,3,4</sup> Its profile is not known for most drugs but *P. yoelii* subsp. *yoelii*, strain YM is resistant to chloroquine.<sup>2,5</sup> The complete genome of *P. yoelii* subsp. *yoelii*, strain YM has been sequenced (BioProject: [PRJEB5705](https://www.ncbi.nlm.nih.gov/bioproject/PRJEB5705)).<sup>6</sup>

*P. yoelii* subsp. *yoelii* is a protozoan parasite that infects mammals other than humans, especially rodents. It is commonly used in rodent model studies of malaria.<sup>7</sup>

#### Material Provided:

Each vial contains approximately 0.5 mL of *P. berghei*-infected mouse blood in Glycerolyte 57 solution (1:2). **This item is host restricted and must be amplified in rodents.** Please refer to Appendix I for cryopreservation instructions.

#### Packaging/Storage:

MRA-755 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended (-130°C or colder). Freeze-thaw cycles should be avoided.

#### Growth Conditions:<sup>8</sup>

*In vivo*, Swiss Webster mouse

#### Inoculation:

1. Thaw a frozen cryovial of MRA-755 in a 35°C to 37°C water bath for approximately 2 to 3 minutes. Do not allow the vial to immerse near the cap line seal while thawing.

2. Once thawed, wipe the outside of the vial with 70% ethanol before opening. Using a 1 mL syringe equipped with a 27-gauge 1/2-inch needle, remove approximately 200 µL to 300 µL from the vial.
3. Wipe the injection site of the mouse with 70% ethanol and inject the sample intraperitoneally at 50 µL to 100 µL per mouse (approximately 3 mice for most applications).

#### Monitoring parasitemia:

1. Starting 3 days post-inoculation, monitor the growth of parasites by tail vein bleed sampling and Giemsa-stained thin blood smear microscopy at 1- to 2-day intervals.
2. Passage the strain when the infection is at or near the first peak of parasitemia (> 5%). This will normally occur within one week of inoculation.

$$\% \text{ parasitemia} = (\text{Infected RBC} / \text{Total RBC}) \times 100$$

#### Passaging:

1. Anesthetize infected mice by CO<sub>2</sub>/O<sub>2</sub> inhalation. Collect the blood by orbital bleeding or from the tail vein into 25 mL of cold 1× PBS-heparin anticoagulant solution (please refer to Appendix I for preparation instructions).
2. Inject the sample into each of the uninfected mice (approximately 10 mice) as described in Inoculation step #3 above.
3. Monitor parasitemia as described above and passage as needed.

Please refer to Appendix I for cryopreservation instructions.

Note: Do not directly inject freshly thawed parasites from cryopreserved stocks by the intravenous (IV) route, as these samples contain cryoprotectant, anticoagulant and may contain traces of lysed or coagulated red blood cells. Direct IV inoculation from cryopreserved stock may result in pulmonary embolism or shock in mice.

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Plasmodium yoelii* subsp. *yoelii*, Strain YM, MRA-755, contributed by David Walliker."

#### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**All blood cultures should be handled with appropriate safety precautions necessary for the handling of bloodborne pathogens. Personnel must be trained in accordance with their institutional policy regarding bloodborne pathogens.**

## Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

## Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

## References:

1. Landau, I. and R. Killick-Kendrick. "Rodent Plasmodia of the République Centrafricaine: The Sporogony and Tissue Stages of *Plasmodium chabaudi* and *P. berghei yoelii*." *Trans. R. Soc. Trop. Med. Hyg.* 60 (1966): 633-649. PubMed: 4163669.
2. Walliker, D., Personal Communication.
3. Yoeli, M., et al. "Sudden Increase in Virulence in a Strain of *Plasmodium berghei yoelii*." *Ann. Trop. Med. Parasitol.* 69 (1975): 173-178. PubMed: 1098585.
4. Walliker, D., et al. "A Genetic Investigation of Virulence in a Rodent Malaria Parasite." *Parasitology* 72 (1976): 183-194. PubMed: 1264490.
5. Warhurst, D. C. and R. Killick-Kendrick. "Spontaneous Resistance to Chloroquine in a Strain of Rodent Malaria (*Plasmodium berghei yoelii*)." *Nature* 213 (1967): 1048-1049.
6. Otto, T. D., et al. "A Comprehensive Evaluation of Rodent Malaria Parasite Genomes and Gene Expression." *BMC Biol.* 12 (2014): 86. PubMed: 25359557.
7. Hall, N., et al. "A Comprehensive Survey of the *Plasmodium* Life Cycle by Genomic, Transcriptomic, and Proteomic Analyses." *Science* 307 (2005): 82-86. PubMed: 15637271.
8. Peters, W. and B. L. Robinson. "Chapter 92 -- Malaria." In *Handbook of Animal Models of Infection*. Eds. O. Zak and M. Sande. London: Academic Press, 1999, pp. 757-773.

ATCC® is a trademark of the American Type Culture Collection.



## APPENDIX I: CRYOPRESERVATION

**Note:** Only immature blood-stage parasites (rings) are viable by this method. Parasitemia of 1% or higher of ring-stage parasites is recommended for cryopreservation. All steps should be carried out in a biosafety cabinet under proper air flow.

1. Prepare a 1× PBS-heparin anticoagulant solution using sterile 1× PBS (pH ~ 7.2) without calcium or magnesium (ATCC® 30-2200™) adjusted to contain 30 Units/mL sterile heparin.
2. Harvest parasitized mouse blood into 25 × volume ice cold sterile 1× PBS-heparin anticoagulant solution and place on ice.
3. Centrifuge the diluted blood culture at 1000 × g for 5 minutes at 4°C.
4. Aspirate the supernatant carefully. Measure the volume of packed red blood cells using centrifuge tube graduations or standard volume controls.
5. To the volume of packed red blood cells, add dropwise one volume of cold (4°C) Glycerolyte 57 solution (Fenwal, Cat. No. 4A7831, or equivalent). Let stand for 5 minutes at room temperature.
6. Add dropwise an additional volume of cold Glycerolyte 57 solution to the pellet. Mix well and aliquot 0.5 mL into 1.5 mL sterile cryopreservation vials.
7. Place the vials in a controlled-rate freezing unit. From room temperature, cool the vials at -1°C/min to -40°C. If the freezing unit can compensate for the heat of fusion, maintain rate at -1°C/min through this phase. At -40°C, plunge vials into liquid nitrogen. Alternatively, place the vials in a Nalgene 1°C freezing container. Place the container at -80°C for 24 to 48 hours and then plunge vials into liquid nitrogen.
8. Store in either the vapor or liquid phase of a nitrogen refrigerator (-130°C or colder).